Therapeutic Antibodies - Ultimately

Twelve of the top-20 medicines are projected to be antibodies by 2024 (Evaluate Pharma, 2019) and sales may top $400B by 2030 (Fatpos Global, March 2021). 85% of approved antibodies were generated with in vivo tools (Antibody Society, October 2020), increasingly transgenic platforms.

Abvivo creates high-performance antibodies against targets with high human-rodent and intra-protein family homology using industry-leading transgenic platforms and a variety of B cell cloning technologies. Partners avoid freedom-to-operate risk and primary discovery steps while obtaining best-in-class antibody development candidates. Ultimately target-solving antibodies.

Abvivo designs and generates antibodies where biopharmaceutical companies have the greatest needs. Flexible alternatives include options, licenses, and asset purchases. Abvivo does not disclose its programs or partners publicly. Ultimately business-promoting antibodies.

Contact bl@abvivo.com for ultimate therapeutic antibody opportunities.